MDT

86.5

0%↓

A

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

A

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

A

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

A

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

A

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

Search

Lisata Therapeutics

Open

5 -0.2

Overview

Share price change

24h

Current

Min

4.99

Max

5.01

Key metrics

By Trading Economics

Income

1.3M

-3M

Sales

100K

100K

Profit margin

-2,954

Employees

21

Dividends

By Dow Jones

Next Earnings

7 May 2026

Market Stats

By TradingEconomics

Market Cap

531K

40M

Previous open

5.2

Previous close

5

Lisata Therapeutics Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2026, 04:27 UTC

Major News Events

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5 Apr 2026, 23:55 UTC

Market Talk

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5 Apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5 Apr 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Apr 2026, 23:42 UTC

Market Talk

China's Consumer Inflation Likely Eased in March -- Market Talk

5 Apr 2026, 23:38 UTC

Market Talk
Major News Events

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5 Apr 2026, 12:57 UTC

Major News Events

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3 Apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 18:30 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 Apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 Apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 Apr 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 Apr 2026, 16:50 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 Apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 16:12 UTC

Earnings

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 Apr 2026, 15:56 UTC

Market Talk
Major News Events

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 Apr 2026, 15:56 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

3 Apr 2026, 15:56 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

3 Apr 2026, 15:20 UTC

Major News Events

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 Apr 2026, 15:08 UTC

Acquisitions, Mergers, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 Apr 2026, 14:11 UTC

Market Talk
Major News Events

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 Apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 Apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 Apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 Apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 Apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 Apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Lisata Therapeutics Forecast

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Pre-tax profit

Sales

Operating profit

$

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
help-icon Live chat